Gleason Score 9-10 vs. Gleason 8 Associated with Worse Outcomes
the Cancer Therapy Advisor take:
Men who have a localized prostate biopsy Gleason 9-10 with definitive local therapy face worse outcomes compared to those with biopsy Gleason 8 disease, according to a recent study published in The Journal of Urology.
Che-kai Tsao, MD, of the Division of Hematology and Medical Oncology at The Tisch Cancer Institute at Mount Sinai in New York observed a cohort of 847 patients with biopsy Gleason 8-10 disease who had received either radiation therapy (RT) or radical prostatectomy (RP) from January 2001 to December 2011.
They used multivariable Cox modeling to compare outcomes in Gleason score of 8 and 9-10 in terms of time to biochemical recurrence, time to metastases, and overall survival. At baseline, patients demonstrated similar characteristics between the two groups.
The researchers found that higher-grade disease was associated with an increased risk of developing metastatic disease, with an increased risk of death in Gleason 9-10, particularly among those treated with RP. Gleason 9-10 was also associated with higher PSA at diagnosis.
“Clinical trials incorporating newer approaches to Gleason 9-10 cancer are urgently needed,” the authors concluded.
Men who have a localized prostate biopsy Gleason 9-10 with definitive local therapy face worse outcomes.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- As HPV-Related Cancer Rates Climb, Experts Scrutinize Barriers to HPV Vaccination
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Duvelisib Delayed Progression in CLL/SLL: Study
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC
- Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia
- BTK Inhibitor Zanubrutinib Appears Promising in Waldenström Macroglobulinemia
- Carfilzomib Regimens Offer a Neuropathy-Sparing Approach in Multiple Myeloma, WM
- Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer